河北中医
河北中醫
하북중의
HEBEI JORNAL OF TRADITIONAL CHINESE MEDICINE
2014年
12期
1783-1784,1785
,共3页
肥胖症%胰岛素%降血脂药(中药)
肥胖癥%胰島素%降血脂藥(中藥)
비반증%이도소%강혈지약(중약)
Obesity%Insulin%Descendens blood fat drugs (traditional Chinese medicine)
目的：观察肥胖1号方治疗脾虚痰湿型肥胖症合并胰岛素抵抗的临床疗效。方法将60例脾虚痰湿型肥胖症合并胰岛素抵抗患者随机分为2组，对照组30例予二甲双胍治疗，治疗组30例在对照组治疗基础上加肥胖1号方。2组均治疗12周后，统计2组治疗前后体质量指数（ BMI ）、胰岛素抵抗指数（HOMA-IR）及血脂变化。结果2组治疗后BMI、HOMA-IR及血脂均较对照组明显改善（P＜0．05）。结论肥胖1号方治疗脾虚痰湿型肥胖症合并胰岛素抵抗疗效确切，安全可靠。
目的：觀察肥胖1號方治療脾虛痰濕型肥胖癥閤併胰島素牴抗的臨床療效。方法將60例脾虛痰濕型肥胖癥閤併胰島素牴抗患者隨機分為2組，對照組30例予二甲雙胍治療，治療組30例在對照組治療基礎上加肥胖1號方。2組均治療12週後，統計2組治療前後體質量指數（ BMI ）、胰島素牴抗指數（HOMA-IR）及血脂變化。結果2組治療後BMI、HOMA-IR及血脂均較對照組明顯改善（P＜0．05）。結論肥胖1號方治療脾虛痰濕型肥胖癥閤併胰島素牴抗療效確切，安全可靠。
목적：관찰비반1호방치료비허담습형비반증합병이도소저항적림상료효。방법장60례비허담습형비반증합병이도소저항환자수궤분위2조，대조조30례여이갑쌍고치료，치료조30례재대조조치료기출상가비반1호방。2조균치료12주후，통계2조치료전후체질량지수（ BMI ）、이도소저항지수（HOMA-IR）급혈지변화。결과2조치료후BMI、HOMA-IR급혈지균교대조조명현개선（P＜0．05）。결론비반1호방치료비허담습형비반증합병이도소저항료효학절，안전가고。
Objective To survey the clinical effect of Feipang Yihao decoction on the treatment of spleen-deficiency and phlegm-turbid stagnation type obesity with insulin resistance Methods 60 cases of spleen-defi-ciency and phlegm -turbid stagnation type obesity with insulin resistance were randomly divided into a treatment group ( treated with Feipang-Yihao Decoction and Metformin) and a control group ( treated with Metformin) ,with 30 cases in each group and performed a therapeutic course for 12 weeks.The clinical efficacy and the change of symptom checklist and BMI,Blood lipid level and HOMA-IR before and after treatment were evaluated.Results After 12 weeks of treatment,BMI,Blood lipid level and HOMA-IR after treatment were obviously improved (P<0.05) as compared with those before treatment in two groups ( P<0.05) .Conclusion Feipang Yihao decoction on spleen-deficiency and phlegm-turbid stagnation type obesity with insulin resistance has safe and reliable curative effect.
